William A. Denny
Corporate Officer/Principal at Auckland University
Profile
William A.
Denny is the founder of Proacta, Inc. (founded in 2001), Pathway Therapeutics, Inc. (founded in 2008), and Pathway Therapeutics Ltd.
(founded in 2008).
Currently, he holds the position of Professor at Auckland University.
William A. Denny active positions
| Companies | Position | Start |
|---|---|---|
| Auckland University | Corporate Officer/Principal | - |
Former positions of William A. Denny
| Companies | Position | End |
|---|---|---|
Pathway Therapeutics, Inc.
 Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Founder | - |
Pathway Therapeutics Ltd.
 Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Founder | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
- Stock Market
- Insiders
- William A. Denny
